Literature DB >> 18252266

Angiotensin II induces matrix metalloproteinase-9 expression via a nuclear factor-kappaB-dependent pathway in vascular smooth muscle cells.

Rui-wei Guo1, Li-xia Yang, Hong Wang, Bei Liu, Lei Wang.   

Abstract

Angiotensin II (AngII) is widely recognized as a critical regulator of the development of atherosclerosis. Matrix metalloproteinases (MMPs) are thought to participate in plaque destabilization through degradation of the extracellular matrix. In the present study, we investigated the potential mechanism of AngII-induced MMP-9 expression in vascular smooth muscle cells (VSMC). AngII upregulated the expression of MMP-9 significantly in VSMC obtained from rat aorta. RNAi-mediated knockdown of p65 and losartan, an inhibitor of AngII receptors subtype-1 (AT1), could abolish AngII-induced MMP-9 expression. In addition, AngII induced the NF-kappaB binding activity via AT1 and AT2 receptors in VSMC, and AngII-induced activation of NF-kappaB is not associated with significant downregulation of IkappaB. In summary, this study demonstrates that AngII stimulates NF-kappaB nuclear translocation in VSMC via AT1 and AT2. AngII increases the expression of MMP-9 in VSMC, and AT1 and NF-kappaB pathways have an important role in this response.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18252266     DOI: 10.1016/j.regpep.2007.12.005

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  21 in total

Review 1.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 2.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

3.  Vascular smooth muscle cell motility: From migration to invasion.

Authors:  Sherif F Louis; Peter Zahradka
Journal:  Exp Clin Cardiol       Date:  2010

Review 4.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

5.  Blockade of AT1 receptors protects the blood-brain barrier and improves cognition in Dahl salt-sensitive hypertensive rats.

Authors:  Nicolas Pelisch; Naohisa Hosomi; Masaki Ueno; Daisuke Nakano; Hirofumi Hitomi; Masaki Mogi; Kenji Shimada; Hiroyuki Kobori; Masatsugu Horiuchi; Haruhiko Sakamoto; Masayasu Matsumoto; Masakazu Kohno; Akira Nishiyama
Journal:  Am J Hypertens       Date:  2010-12-16       Impact factor: 2.689

6.  The effect of the expression of angiotensin II on extracellular matrix metalloproteinase inducer (EMMPRIN) in macrophages is mediated via the AT1/COX-2/PGE2 pathway.

Authors:  Li-xia Yang; Jin-shan Ye; Rui-wei Guo; Hong Liu; Xian-mei Wang; Feng Qi; Chuanming Guo
Journal:  Inflamm Res       Date:  2010-06-20       Impact factor: 4.575

7.  Caveolin 1 is critical for abdominal aortic aneurysm formation induced by angiotensin II and inhibition of lysyl oxidase.

Authors:  Takehiko Takayanagi; Kevin J Crawford; Tomonori Kobayashi; Takashi Obama; Toshiyuki Tsuji; Katherine J Elliott; Tomoki Hashimoto; Victor Rizzo; Satoru Eguchi
Journal:  Clin Sci (Lond)       Date:  2014-06       Impact factor: 6.124

8.  Angiotensin II increases matrix metalloproteinase 2 expression in human aortic smooth muscle cells via AT1R and ERK1/2.

Authors:  Chunmao Wang; Xiangyang Qian; Xiaogang Sun; Qian Chang
Journal:  Exp Biol Med (Maywood)       Date:  2015-03-11

9.  Mmp-9, a potential target for cerebral ischemic treatment.

Authors:  Xue Dong; Yu-Ning Song; Wei-Guo Liu; Xiu-Li Guo
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

10.  Diminazene enhances stability of atherosclerotic plaques in ApoE-deficient mice.

Authors:  Rodrigo A Fraga-Silva; Fabrizio Montecucco; Fabiana P Costa-Fraga; Alessio Nencioni; Irene Caffa; Maiia E Bragina; François Mach; Mohan K Raizada; Robson A S Santos; Rafaela F da Silva; Nikolaos Stergiopulos
Journal:  Vascul Pharmacol       Date:  2015-08-22       Impact factor: 5.773

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.